angiotensin ii acetate · La Jolla Pharma · NDA 209360
Giapreza
Earliest generic entry, as listed · earliest of 2 marketed strengths
6 Jan 2037
Blocked by patent: US 11219662. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 11 unexpired
16 Orange Book listing rows for 11 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 11219662 | use U-3262 · sets the listed date | 6 Jan 2037 |
| US 10028995 | use U-2338 | 18 Dec 2034 |
| US 10493124 | use U-2679 | 18 Dec 2034 |
| US 11096983 | use U-3211, U-3212 | 18 Dec 2034 |
| US 11096983 listing row | use U-3211 | 18 Dec 2034 |
| US 11096983 listing row | use U-3212 | 18 Dec 2034 |
| US 11559559 | use U-3514 | 18 Dec 2034 |
| US 9220745 | use U-2217, U-2218 | 18 Dec 2034 |
| US 9220745 listing row | use U-2217 | 18 Dec 2034 |
| US 9220745 listing row | use U-2218 | 18 Dec 2034 |
| US 9572856 | use U-2221 | 18 Jul 2031 |
| US 9572856 listing row | use U-2221 | 20 Nov 2030 |
| US 9572856 listing row | use U-2221 | 18 Jul 2031 |
| US 10335451 | use U-2581 | 16 Dec 2029 |
| US 10500247 | use U-2680, U-2681 | 16 Dec 2029 |
| US 10500247 listing row | use U-2680 | 16 Dec 2029 |
| US 10500247 listing row | use U-2681 | 16 Dec 2029 |
| US 10548943 | use U-2739, U-2740 | 16 Dec 2029 |
| US 10548943 listing row | use U-2739 | 16 Dec 2029 |
| US 10548943 listing row | use U-2740 | 16 Dec 2029 |
| US 9867863 | use U-2231 | 16 Dec 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209360 · 001 · RLD | solution, intravenous | EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) | 6 Jan 2037 |
| 209360 · 002 · RLD · discontinued | solution, intravenous | EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) | 6 Jan 2037 |
| 209360 · 003 · RLD | solution, intravenous | EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) | 6 Jan 2037 |